StockNews.com Upgrades Kura Oncology (NASDAQ:KURA) to “Buy”

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a report issued on Friday morning.

KURA has been the subject of several other research reports. Jefferies Financial Group decreased their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Scotiabank decreased their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, March 4th. Finally, UBS Group cut their price target on Kura Oncology from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $25.50.

Kura Oncology Trading Down 2.2 %

Shares of KURA stock opened at $7.53 on Friday. The stock has a market cap of $608.09 million, a price-to-earnings ratio of -3.19 and a beta of 0.85. The stock has a 50-day moving average of $8.00 and a 200-day moving average of $13.29. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. On average, equities research analysts forecast that Kura Oncology will post -2.44 earnings per share for the current year.

Insider Activity

In other news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,729 shares of company stock worth $92,307 over the last 90 days. 5.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Kura Oncology

Hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its holdings in Kura Oncology by 104.5% during the third quarter. Barclays PLC now owns 165,484 shares of the company’s stock worth $3,234,000 after acquiring an additional 84,563 shares during the period. SG Americas Securities LLC bought a new stake in Kura Oncology during the fourth quarter worth $436,000. Moody Aldrich Partners LLC lifted its holdings in Kura Oncology by 42.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock worth $1,251,000 after acquiring an additional 42,712 shares during the period. Harbor Capital Advisors Inc. lifted its holdings in Kura Oncology by 4.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after acquiring an additional 2,076 shares during the period. Finally, Jennison Associates LLC bought a new stake in Kura Oncology during the fourth quarter worth $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.